Abstract The course of HIV infection has been dramatically transformed by the success of antiretroviral therapy from a universally fatal infection to a manageable chronic disease. With these advances in HIV disease management, age-related comorbidities, including metabolic bone disease, have become more prominent in the routine care of persons living with HIV infection. Recent data have highlighted the role of HIV infection, initiation of antiretroviral therapy, and hepatitis C virus coinfection in bone mineral density loss and fracture incidence. Additionally, the underlying mechanism for the development of metabolic bone disease in the setting of HIV infection has received considerable attention. This review highlights recently published and presented data and synthesizes the current state of the field. These data highlight the need for proactive prevention for fragility fractures.
Introduction
Among HIV-infected individuals who successfully engage in care, combination antiretroviral therapy (cART) has resulted in dramatic reductions in HIV-associated morbidity and mortality, increased life expectancy, and an increase in age-related comorbidities. Clinicians are reporting a premature aging phenotype among HIV-infected individuals, manifest by an increasing incidence of therapy-related metabolic complications, including frailty, neurocognitive dysfunction, hyperlipidemia, insulin resistance, diabetes mellitus, cardiovascular disease, and osteoporosis and related fractures [1, 2] . Specifically, low bone mineral density (BMD) is a frequent complication of HIV infection and/or its treatment with cART [3] . Several cohort studies have shown that a majority of HIVinfected persons have low BMD despite the fact that most of the HIV-infected persons included in these studies were under the age of 50 years, an age below which osteoporosis is a rare diagnosis in the general population [4, 5] . Metabolic bone disease may have a dramatic impact on the health of the HIV-infected population, as multiple studies shown that HIV-infected individuals experience significantly elevated rates of bone fractures [6] . This review focuses on recent data related to three areas of interest in HIV-related metabolic bone disease: the effects of specific antiretroviral strategies, possible mechanisms for BMD loss, and the risk of fracture.
ARTand Bone Loss
The expanding list of available antiretroviral agents allows care providers to develop a myriad of virologically suppressive regimens, but how do these affect bone health? Given that tenofovir (TDF) has been consistently associated with BMD loss, numerous studies have looked at alternatives to this agent. One approach is switching from TDF to an alternative agent. At the 2012 Conference on Retroviruses and Opportunistic Infections (CROI), Negredo reported a small study assessing 54 persons on a suppressive TDF-containing regimen who either continued TDF (n= 28) or switched to abacavir (ABC, n=26) [7] . Those persons who switched to ABC had a 2.1 % increase in BMD at the femoral neck while there was no change in the TDF group (p=0.04). In the lumbar spine, the ABC switch group experienced a 0.2 % increase in BMD at 48 weeks while the TDF group had a 2.9 % decrease in BMD (p=0.09). At CROI 2013, Bloch reported a study evaluating an open-label switch from TDF to raltegravir (RAL), an integrase inhibitor, in 37 persons with fully suppressed HIV viremia and a femoral neck T score of≤−1.0 [8] . There were significant increases in BMD in the lumbar spine, femoral neck and total hip (1.5 %, 2.1 %, and 2.5 %, respectively; p<0.05 for all). Markers of both bone formation (osteocalcin) and resorption (N-telopeptide and bone alkaline phosphatase) had declined significantly at both week 24 and week 48. These studies suggest that switch strategies may be an effective approach to mitigate TDF-associated bone loss, although clinical guidance regarding which patients to switch remains undefined.
Given the specific concern of bone toxicity from nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), other studies have evaluated bone markers during treatment with novel NRTI-sparing regimens. The RADAR study, presented at the 2013 International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS), presents a cautionary tale [9] . Ritonavir-boosted darunavir (DRV/rtv) was paired with either RAL or TDF/ emtricitabine (TDF/FTC) in 80 ART-naive persons. After 48 weeks of treatment, the RAL arm showed a 1.2 % increase in total body BMD while the TDF/FTC arm experienced a 0.7 % loss. Bone biomarkers remained stable over 48 weeks in the RAL arm but increased significantly in the TDF/FTC arm. Unfortunately, HIV virologic suppression was maintained less effectively in the RAL arm (63 % vs. 83 % at 48 weeks, p= 0.045), highlighting the importance of focusing first on virologic success before considering metabolic consequences.
Data from a virologically successful NRTI-sparing regimen have also been presented. Hoy presented 96-week data from the SECOND-LINE study at IAS 2013 comparing two second-line regimens: lopinavir/ritonavir (LPV/ rtv) combined with either RAL or two or three NRTIs [10] . Those persons randomized to the NRTI arm had significantly greater bone loss in both the proximal femur (−5.2 % vs. −2.9 %, p< 0.001) and the lumbar spine (−4.2 % vs. −2.0 %, p<0.001). A multivariate analysis showed that BMD loss was independently associated with lower body mass index (BMI), exposure to TDF, and nonAsian ethnicity. Another NRTI-sparing study (INROADS) was presented at the 15th International Workshop on Comorbidities and Adverse Reactions [11] . In this single arm study, 54 HIV-infected persons, including 12 ARTnaive persons with baseline resistance to NNRTIs, and 42 persons with previous failure of an ART regimen including a protease inhibitor (PI), were given DRV/rtv with etravirine. At 48 weeks, there was no change in median BMD in the total hip (1.0 g/cm 2 at both time-points) and a nonsignificant decline in BMD in the lumbar spine (1.2 to 1.1 g/cm 2 ). Taken together, these three studies show that BMD loss can be reduced by the selection of NRTI-free (specifically a TDF) regimen.
Alternative NRTI strategies for ART-naive subjects have also been explored. Moyle and colleagues recently reported 96-week data from an open-label randomized study that evaluated bone, renal and metabolic consequences of treatment with efavirenz paired with either TDF/FTC or ABC/lamivudine (ABC/3TC) [12] . Of 385 subjects enrolled, 249 completed the study. Total hip BMD declined in both groups with the greatest decline in the first 48 weeks and stabilization in the second 48 weeks. At 96 weeks, total hip BMD loss was significantly greater in the TDF/FTC arm than in the ABC/3TC arm (−3.6 % vs. −2.2 %, p<0.001). Similarly, ABC/3TC was associated with less bone loss in the lumbar spine (−0.8 % vs. −1.9 %, p=0.112). Wohl recently presented data from the ASSURE study comparing unboosted atazanavir (ATV) with ABC/3TC to ritonavir-boosted ATV (ATV/ rtv) with TDF/FTC in 296 ART-naive subjects who were HLA B*5701-negative [13] . In this study, changes in markers of bone formation and turnover were evaluated. In the ABC/3TC arm, there were reductions in markers of bone formation (osteocalcin) and bone resorption (Ctelopeptide and bone alkaline phosphatase) as well as parathyroid hormone, while the markers were relatively stable in the TDF/FTC arm. The differences in the changes in these markers was highly significant (p<0.001 for all). The mean 25-OH vitamin D levels declined in the ABC/ 3TC group (28 to 25 ng/mL) and increased in the TDF/ FTC/rtv group (26 to 29 ng/mL, p<0.05 for both). These two studies confirm previous studies showing that ABC/ 3TC is associated with less BMD decline and bone turnover than TDF/FTC [14••, 15] .
Perhaps more provocative on the ART front has been the arrival of tenofovir alafenamide fumarate (TAF), an investigational tenofovir prodrug. Zolopa presented 24-week data from the phase 2 trial at CROI 2013 comparing TAF and TDF combined with elvitegravir, cobicistat, and FTC in ART-naive persons [16] . Bone loss was significantly reduced in those receiving TAF in both the lumbar spine (−0.8 % vs. −2.5 %, p=0.002) and the total hip (−0.3 % vs. −2.0 %, p<0.001). Subsequent 48-week data from this study confirmed the superiority of TAF over TDF in both the total hip (−0.6 % vs. −2.4 %, p<0.001) and the lumbar spine (−1.0 % vs. −3.4 %, p<0.001) [17] . Specifically, no decline in total hip BMD was seen in 32 % persons in the TAF arm compared to only 7 % in the TDF arm (p<0.001). Markers of bone formation and resorption increased to a greater degree over the 48 weeks in the TDF arm: N-terminal propeptide of type I collagen (109 % vs. 169 % baseline value) and C-terminal telopeptide of collagen (CTx, 119 % vs. 178 %, p<0.001 for both). Taken as a whole, TDF-sparing regimens, regardless of the agents chosen, significantly reduce BMD loss.
Mechanisms Behind Bone Loss
The pathogenesis of bone disease among people living with HIV infection is unclear, but is an area of active research. Several groups have focused on different aspects of the pathogenesis. Failure to reach peak BMD is commonly cited as a cause for the low BMD in persons who are infected with HIV before the age of 30 years, the age at which peak BMD is achieved. Tanchaweng presented data on changes in BMD among 46 HIV-infected Thai adolescents [18] . At a median age of 14.5 years, 23 % had low BMD (defined as a z-score of <−2.0) and 19 % had low BMD when reevaluated 2 years later. Only male sex was associated with low BMD. Notably no ART agents, and specifically TDF, were associated with low BMD. The limited sample size likely provided inadequate power to demonstrate any effect related to ART. In another cohort study, Yin and colleagues compared BMD in 30 HIVinfected young adults with that in 15 uninfected young adults (ages 20−25 years) [19••] . The HIV-infected subjects were all receiving ART; 15 were infected perinatally and 15 during adolescence. By routine DXA scanning, the HIV-infected subjects had lower z-scores at all sites evaluated (spine, total hip, radius). CTx, a marker of bone resorption, was significantly higher in the HIV-infected subjects. These investigators also utilized high-resolution CT scanning at the distal radius and tibia and demonstrated that HIV-infected subjects had reduced trabecular BMD and cortical thickness at these sites indicating a reduction not only in bone mass but also in bone strength. In another observational study presented at CROI, Jiminez reported BMD data from a cohort of 24 perinatally infected children and identified low BMD (defined as a zscore of<−1.0) in 38 % of the cohort [20] . Low BMD was associated with the nadir CD4 count and time with detectable HIV viremia but not with TDF exposure or markers of systemic inflammation. Taken as a whole, these studies indicate that a significant proportion of HIV-infected young adults fail to achieve peak BMD, although the factors driving this process remain to be fully elucidated.
The association between the severity of HIV disease and lower BMD is well established. A recent analysis by Grant and colleagues from the AIDS Clinical Trials Group demonstrates that the loss of BMD on ART initiation is greatest in those individuals with a low CD4 cell count, particularly those with a CD4 count <50 cells/mm 3 [21•] . Additional factors that were independently associated with BMD loss included older age, female sex, lower BMI, higher HIV-1 plasma viral loads, initiation of PI therapy, and initiation of TDF therapy. A separate analysis by Erlandsen et al. (CROI 2013) confirmed the relationship between low nadir CD4 levels and BMD loss during ART initiation [22] .
Another mechanistic study presented at CROI 2013 focused on the role that B cells play in osteoclast activation and increased bone resorption. Titanji presented a crosssectional evaluation including 45 HIV-infected and 45 seronegative persons [23] . Evaluation of the B cells from these two groups showed that intracellular levels of osteoprotegerin (OPG) was reduced and receptor activator of nuclear factor kappa-B ligand (RANKL) was increased in HIV-infected persons. RANKL binds to osteoclasts to increase bone resorption while OPG binds to RANKL to prevent its action on osteoclasts. The HIV-infected persons had elevated markers of bone turnover (CTx) while markers of bone formation (osteocalcin) were similar between the groups. These data suggest that aberrant B cell activity in HIV infection contributes to bone loss by increasing osteoclast activity. Given that B cell dysfunction is a prominent component of advanced HIV disease, this may partially explain why advanced HIV disease is associated with greater BMD loss.
As noted above in the study by Grant et al., an association between PIs and low BMD has long been recognized [3, 24] . A provocative presentation at CROI 2013 by Beaupere focused on the toxicity of HIV proteins and two boosted PIs (ATV/rtv and DRV/rtv) on osteoblast and adipocyte development [25•] . Both cell types are derived from mesenchymal stem cells (MSC). In the presence of HIV proteins or these boosted PIs, the MSCs showed a loss in proliferative capacity, increased reactive oxygen species production, and increased expression of senescence markers and markers of cellular aging (farnesylated prelamin A). Strikingly, differentiation into osteoblasts and adipocytes was greatly reduced as a consequence. Hence, the authors provide a potential mechanism by which this class of agents induces bone loss: a reduction in bone formation due to inhibition of osteoblast formation and imbalance towards bone turnover. A final experiment by this group demonstrated that the disruption of osteoblast formation was corrected by administration of pravastatin, suggesting that bone loss due to PIs could be abrogated by blocking the mevalonic acid pathway and hence demonstrating positive nonlipid effects of statins.
Clearly, antiretroviral agents that induce less bone loss than TDF are of interest but we must be mindful to select ART regimens that will durably suppress HIV viremia. The next steps are to understand the causes of bone loss among our patients and the mechanisms behind this process. To further explore the reduced loss of BMD with TAF, Liu et al. studied the in-vitro effects of TAF on osteoblasts at concentrations that are achieved with oral therapy [26] . First, the authors demonstrated that in-vitro drug levels achieved in osteoblasts are similar to in-vivo levels achieved in lymphocytes. Second, at clinically relevant concentrations, TAF induced no cytotoxic effects on osteoblasts with normal cell viability in vitro.
Thus, a possible explanation for the improved BMD outcomes seen with TAF as compared to TDF relate to lessened osteoblast toxicity and hence normal bone turnover.
Taken together, these studies highlight several key aspects of bone disease pathogenesis: (1) initiating ART earlier in HIV disease progression makes a positive impact on preservation of BMD, (2) we should not forget the relationship between lean body mass and BMD and to counsel patients to perform weight-bearing exercise, and (3) as noted above, the selection of initial regimen plays a big role in bone health. If we have an equivalent regimen for viral efficacy, we should consider regimens with better toxicity profiles.
HIVand Fractures
While the relationship between BMD loss and ART and the mechanism involved in this process are intriguing, the key question for many is: does BMD loss lead to increased fractures? In 2013, the National Osteoporosis Foundation (NOF) included HIV infection and ART as risk factors for osteoporosis and fragility fractures [27] . In support of this, several cohort studies have previously concluded that when matched for age and gender, people living with HIV infection are at greater risk of bone fractures. For example, a nearly threefold higher incident fracture rate was identified among participants in the HIV Outpatient Study (HOPS) than among those participating in the National Hospital Ambulatory Medical Care Survey (NHAMCS-OPD), a representative sample of the US general population. This study suggested that younger HIVinfected adults, particularly those between the ages of 25 and 54 years, are at increased risk of bone fracture [28] .
Interesting data were presented at CROI 2013. Warriner reported a study using US Medicare data comparing the fracture risk in a cohort of 2.5 million HIV-negative and 13,000 HIV-infected persons. In the final adjusted model, the risk of any fracture was approximately 50 % higher in the HIV-infected population than in the HIV-uninfected population. This risk was greater in older HIV-infected patients (>65 years of age; relative risk 1.52; 95 % confidence interval, CI, 1.34 -1.73) but was still present in younger HIV-infected patients (<65 years of age; relative risk 1.32; 95 % CI 1.21 -1.45), and the authors suggest that osteoporotic fractures may occur at younger age among in HIV-infected persons [29] . Gotti provided data demonstrating the need to consider occult spinal fractures. In a cohort of 175 HIV-infected and 120 uninfected age-matched patients, 30 % of HIV-infected patients had morphometric vertebral fractures compared with 4 % of the uninfected patients. Vertebral fracture risk factors included age, osteoporosis, BMI >25 kg/m 2 , AIDS event and TDF. The authors suggest that screening for vertebral fractures is useful and may provide a rationale to begin earlier treatment in patients with osteopenia [30] .
At the 2013 Joint Session of the 15th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV and the 14th European AIDS Conference, Battalora reported on fracture risk among 1,008 HIV-infected participants (median baseline age 42 years) from two Centers of Disease Control and Prevention-funded cohorts in the US that had baseline DEXA testing [31] . During 5,032 person-years of observation, 95 incident fractures occurred, including rib/ sternum (n=18), hand (n=17), foot (n=15) and wrist (n=11). In multivariate analyses, baseline osteoporosis (adjusted hazard ratio, aHR, 3.04; 95 % CI 1.47−6.30) and increasing age (aHR 1.35 per 10 years; 95 % CI 1.07−1.70) were associated with incident fracture. These data provide an important link between the presence of low BMD and the risk of future fracture, even among young adults.
The role of specific ARVs and the relationship to therapy initiation remain an area of controversy. In a recent study, Bedimo and colleagues characterized the risk of osteoporotic fractures (defined as wrist, vertebral or hip fracture) among a cohort of 56,600 HIV-infected veterans identified in the Veteran's Health Administrative Data Clinical Case Registry (VHA CCR) [32] . Cumulative exposure to the antiretrovirals TDF and LPV/rtv was independently associated with the risk of fracture. Another recent study evaluated fracture risk after ART initiation among 4,640 HIV-infected individuals [33] , identifying 135 persons who experienced 151 incident fractures occurring a median 2.3 years after ART initiation. Fracture rates were significantly higher in the first 2 years after ART initiation compared to subsequent time periods. Interestingly, type of ART, baseline CD4 count and HIV viral load were not associated with fracture incidence. The authors suggest that BMD decline on ART initiation is linked to change in bone mass and quality leading to increased fracture risk. Further, as patient health improves over time with ART, the risk of falls and subsequent fractures may decrease with overall improved health, suggesting that there may be a catabolic window after ART initiation that leaves patients susceptible to fracture.
Several studies have focused on the contribution of chronic hepatitis C virus (HCV) and fracture risk among HIV-infected person. In an analysis utilizing Medicaid data from five states comparing fracture rates among 36,950 HCV/HIV coinfected, 276,901 HCV monoinfected, 95,827 HIV monoinfected and 3,110,904 HCV/HIV-uninfected persons, Lo Re and colleagues found that fracture incidence rates were lowest among uninfected persons (1.29 events/1,000 person-years), and increased with either HIV infection (1.95 events/1,000 personyears) or HCV infection (2.69 events/1,000 person-years) [34] . Increasing relative hazards of hip fracture were found in patients with HCV/HIV coinfection compared with those with HCV monoinfection (HR 1.38 [35] . HIV-infected patients had increased risk of fracture (incidence rate ratio, IRR, 1.5; 95 % CI 1.4−1.7) compared with uninfected subjects. Relative risk was lower in HIV monoinfected patients (IRR 1.3; 95 % CI 1.2−1.4) than in HIV/HCV coinfected patients (IRR 2.9; 95 % CI 2.5−3.4). The increased fracture risk with HCV infection and with HIV infection appears to be additive.
Analysis of fracture risk factors among HIV-infected veterans followed in the VHA CCR found that HCV coinfection is associated with a 24 % increased relative risk of osteoporotic fracture over HIV alone and HCV is an independent risk factor for fracture when the model is controlled for cirrhosis [36] . Womack and colleagues assessed the risk of first fragility fracture among 40,115 HIV-infected veterans followed in the Veterans Aging Cohort Study (VACS) and failed to confirm an association with HCV infection [37] . This study included 588 fragility fractures (210 hip, 111 vertebral, and 267 upper arm fractures) and included a majority of patients with uncontrolled HIV viremia. The authors speculated that by accounting for fibrosis using FIB-4 in the models reduced any impact of HCV infection. These disparate results raise questions related to the overall impact of chronic HCV infection on metabolic bone disease. Additional research is warranted to determine whether the role of HCV can be attributable to fibrosis and the development of cirrhosis rather than to a specific viral effect.
Conclusions
It is clear that HIV, particularly advanced disease, and ART initiation play a significant role in the bone health of people living with HIV infection. We must be wise in assessing the baseline risk factors and in selecting the initial ART to achieve virologic success and minimize potential metabolic toxicities such as low BMD and subsequent fractures. ART initiation not only induces a 2−6 % loss in BMD but also leaves patients susceptible to fractures in this early catabolic window period. The mechanisms causing bone loss in patients after ART initiation are likely complex and include viral, medication, host and environmental factors. We must take a proactive approach to prevention to minimize the consequences of bone loss and the morbidity associated with fragility fractures [38•] .
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